The medtech company is looking at explosive growth with sugarBEAT launching in the UK, followed by the rest of Europe. Nemaura Medical, Inc. (NMRD), is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. Continuous Glucose Monitor (CGM) for. SugarBEAT®, Nemaura’s patented, CE marked, needle-free CGM that is non-invasive, affordable, and painless, is easily applied to the skin via a small unobtrusive patch. The devices and sugarBEAT are offered with BEATdiabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching. The Company is a publisher. For more information visit: www.NemauraMedical.com. commercialization of sugarBEAT, a. non-invasive, affordable and flexible. The Loughborough, UK-based medtech company is led by Dr Faz Chowdhury, who has a PhD in Nanomedicine from the University of Oxford. The genius of sugarBEAT lies in its skin-patch technology which allows for better glucose management. The company’s BEAT technology has applications in athletic performance monitoring through lactate monitoring. ", "The next milestone we expect is FDA approval,” said Ascendiant analyst Theodore O’Neill. Nemaura Medical Inc (NASDAQ:NMRD), a medical technology company, has developed SugarBEAT, the world’s first non-invasive continuous glucose monitor (CGM) for people with diabetes and pre-diabetes. The device transmits blood glucose data to users and/or healthcare professionals via a mobile app to allow for better monitoring or treatment. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT and BEATdiabetes. "We are pleased to have submitted our De … Nemaura Medical, Inc. (NMRD), is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. Company to Participate in RedChip Webinar on Tuesday, July 7, at 11 a.m. Data delayed 15 minutes unless otherwise indicated. The pharmaceutical scientist holds 50 patents on drug delivery systems and sensors across 15 technology platforms. sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which help … Nemaura also strengthened its financial position by reducing research and development as well as general and administrative expenses in the first fiscal quarter of 2020. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. “Our ability to simultaneously launch product in the US under the wellbeing category also provides a significant commercial opportunity. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the U.S., risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. The UK-based medtech company has developed sugarBEAT, the world’s first painless, non-invasive glucose monitor, Nemaura is a player in the digital healthcare revolution through its offerings enveloping Artificial Intelligence, devices and digital platforms, In addition to sugarBEAT, the company plans to launch a health subscription service and its proBEAT wellbeing device in the US, Near-term revenue from sugarBEAT’s UK commercialization as it has received its CE mark and is currently in production, After the first wave of shipments to the UK, the company plans to launch sugarBEAT in Germany at a price comparable to the cost of using glucose meters and strips, There’s massive upside potential as Nemaura has submitted a Premarket Approval application to the US FDA for sugarBEAT, Nemaura is also gearing up to sell its glucose device in other geographies like the Middle East and Australia that accept CE Mark approval, On a long-term basis, the company will gain traction from its plan to launch a health subscription service and its proBEAT wellbeing device in the US, It's a win-win as Nemaura establishes itself as a player in the booming digital healthcare space by cutting deals and embracing AI, devices, and digital platforms, Beyond diabetes and glucose trend management, BEAT technology has applications in athletic performance monitoring (lactate monitoring) and alcohol addiction recovery through continuous alcohol monitoring. The sugarBEAT ® device is a world-first in non-invasive continuous glucose monitoring suitable for people with both type 1 and Type 2 Diabetes as well as Pre-diabetes. The FDA reserves the right to re-evaluate their decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. The intended use of sugarBEAT® is for persons with diabetes as an adjunct to finger prick testing to monitor and track their glucose profiles, so that the user can be better informed about the factors affecting their glucose profile, and to help manage their diabetes or potentially reverse their diabetes in the case of Type 2 diabetes. NA Proactive news snapshot: ElectraMeccanica, Vuzix, CleanSpark, Alpine 4... Alpine 4 Technologies stock soars as its board votes to uplist to NASDAQ,... Nemaura Medical announces official US launch of flagship program... Nemaura Medical re-launches corporate website and its flagship... Nemaura Medical licenses Type 2 diabetes weight management mobile app. View source version on businesswire.com: https://www.businesswire.com/news/home/20200707005378/en/, Investor Contact:Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498dave@redchip.com, Peça seu cartão de crédito Santander 100% online, https://www.redchip.com/corporate/webinar_register/64, https://www.businesswire.com/news/home/20200707005378/en/. “Nemaura has game-changing technology to help those with diabetes and those who want to improve and extend life spans,” said O’Neill. It. Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT™diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced it has submitted its PMA application for sugarBEAT® to the United States Food and Drug Administration (FDA) through the eCopy (electronic copy) program submission process. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. The company recently inked a letter of intent to acquire diabetes firm Healthimation LLC which it believes this could complement proBEAT. Nemaura believes that by adapting the sensor chemistry, algorithm and mobile app interface initially developed for sugarBEAT, the BEAT platform has the potential to be utilized for several markets beyond glucose monitoring and diabetes. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the onset of diabetes. Loughborough,England, May 29, 2019 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, … ET to Discuss Commercialization Progress. Healthimation is commercializing an application-based diabetes prevention program that has been developed over 12 years and is supported with clinical data. Abbott’s Freestyle Libre 14-day system generates strong sales and netted roughly $1 billion in sales in 2018. Nemaura Medical is a New York-based medical technology player that essentially operates in the diagnostic medical devices space. Contact the author Uttara Choudhury at [email protected], Create your account: sign up and get ahead on news and events. Bucking the trend for sensors aimed at people on insulin, the company’s intention is to focus on people with Type 2 diabetes (though obviously not disallowing anyone with Type 1 to use their sensor if … sugarBEAT is targeted initially at the Type 2 diabetic population, which number is greater than 25 million people in the U.S. CEO Dr. Faz Chowdhury will be participating in an investor webinar, hosted by RedChip Companies, on Tuesday, July 7, 2020 at 11:00 a.m. proBEAT™ comprises a non-invasive glucose monitor and a digital healthcare subscription service and is due to be launched in the US as a general wellness product. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company... Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Tesla Inc: A new year, but the same old shorts for Elon? Given the high rate of diabetes, Europe represents a $3 billion market opportunity, while the United States is a $4 billion market. O’Neill said the “fastest growing adopter group” for sugarBEAT will be biohacking’s poster boys like Geoffrey Woo, cofounder and CEO of specialized foods company HVMN and Twitter Inc (NYSE:TWTR) CEO Jack Dorsey. He is the inventor and driving force behind sugarBEAT. With the help of a Nano-sensor, the patch measures the molecules, giving the person a quick clinical read and diagnosis. NA Proactive news snapshot: KULR Technology Group, Canntab Therapeutics, Falcon Gold, CytoDyn. proBEATTM will be introduced as a wellbeing device whereby we will be collecting glucose profiles and developing artificial intelligence-based prompts and feedback on how different factors affect glucose levels to help people make informed lifestyle choices". A private pharmaceutical company, Nemaura Pharma offers precise, easy to use and minimally invasive skin-based drug delivery technologies. The insertion is painful, to put it mildly. The device, by Nemaura Medical, has an in-built temperature sensor that can continuously track body temperature through the skin, which could help in the battle against coronavirus. In addition, Nemaura is evaluating new applications for continuous lactate monitoring (CLM) using its BEAT platform to keep tabs on disease progression in coronavirus (COVID-19) patients. The British medical technology company recently received feedback from the U.S. Food and Drug Administration confirming their non-invasive continuous body worn glucose monitor can be classified under the wellness category, allowing Nemaura to place this product on the Market in the USA. The device, which is a CE approved Class IIb medical device, sits on the top of the arm and measures blood glucose … To accelerate its commercial strategy, the company as of August had about $18 million in cash to help fund the commercialization of its diagnostic devices and subscription services. Nemaura Medical is a UK based Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBEAT. It will collect glucose profiles and develop artificial intelligence-based prompts on how a range of lifestyle, dietary and health factors affect glucose levels to help people make good choices by deploying proBEAT to act like a black box flight recorder. We intend to take full advantage of this opportunity, given the sheer scale of the market in the US.”, Analysts at Ascendiant Capital Markets initiated coverage of Nemaura with a Buy rating, noting that CE mark approval was an "exciting achieved milestone. Nemaura Medical, Inc. (NMRD), is a medical technology company commercializing sugarBEAT ® and BEAT ® diabetes. Whilst the PMA application is under review for approval of sugarBEAT® as a Class III medical device, we plan to launch proBEAT™ in the USA later this year. Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which … Full interview: Nemaura Medical reveals details of upcoming European launch... Alpine 4 Technologies looks to take major step by uplisting to a... Arizona Silver Exploration closes private placement bringing in... Elys Game Technology hire new CEO to play and win in the gaming... Progressive Planet ramps up production and potential revenue by... CleanSpark outlines its 2021 growth plans as it ramps up Bitcoin... American Manganese provides review of 2020 company and industry... Gevo gets 12-month target price increase by Noble Capital to $5.00... InnoCan Pharma announces the closing of its C$2.4M private placement. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT® and BEAT®diabetes. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC. The analyst said Nemaura is targeting a $179 billion global market opportunity including insulin and non-insulin dependent diabetics, pre-diabetics, and wearable health-tech markets. Based on recently published independent clinical evaluations, the company recently said “measurement of blood lactic acid has been established as an indicator for disease progression in COVID-19 patients” which could be an additional target market. Nemaura Medical Inc. Nemaura Medical, Inc. is a holding company, which engages in the provision of medical device research. Nemaura Medical, Inc. (NASDAQ: NMRD) (Nemaura or the Company), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT, its non-invasive and flexible continuous glucose monitor (CGM), together with BEAT„¢diabetes, a planned health subscription service designed to help people with Type 2 diabetes … Select the link below to download: – Continuous Glucose Monitoring in Hospitalised and Quarantined Patients with COVID-19 19/08/2020 Lactate Monitoring In Critical Care and Monitoring Disease Progression in Covid-19 14/07/2020 Management of Type 2 Diabetes using non-invasive CGM 11/05/2020 Continuous Temperature Monitoring – Use in Fever Detection and Other Areas … Nemaura Medical is a Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBEAT. Nemaura Medical Inc (NASDAQ:NMRD) is developing micro-systems based wearable diagnostic devices and commercializing sugarBEAT, the world’s first non-invasive continuous glucose monitor (CGM) for people with diabetes and pre-diabetes. “This is a very exciting period for Nemaura Medical as it has steadily transitioned toward commercialization of its lead product, sugarBEAT, initially in the UK and Germany,” said Nemaura Medical CEO Faz Chowdhury. Terms of use. Nemaura Medical Inc (NASDAQ:NMRD) is developing micro-systems based wearable diagnostic devices and commercializing sugarBEAT, the world’s first non-invasive continuous glucose monitor (CGM) for people with diabetes and pre-diabetes. “The technology has additional target markets that will also be pursued including continuous lactate monitoring which is aimed at elite athletes, those who train to become elites and those that simply want to perform at their best.”. Tesla Inc: Will Plaid be in fashion for 2021? Tesla Inc: Elon Musk, the Boring Company and his journey to centre of the earth (or beneath the streets of Las Vegas, at least). Nemaura Medical (NSDQ:NMRD) this week said it submitted a De Novo medical device applications to the FDA for its SugarBEAT non-invasive glucose monitor. During the presentation, Dr. Chowdhury will provide an update on the Company’s developments, including commercialization progress, U.S. product launch, and status of collaborative partnerships, as well as update on a continuous temperature monitor (CTM) for both the diabetes and non-diabetes markets. A live Q&A session with Dr. Chowdhury will follow the presentation. The company was founded by Dr Faz Chowdhury in 2013. The US represents the largest single market for sugarBEAT, according to the company. SugarBEAT® is the World’s First Non-Invasive Continuous Glucose Monitor. Based in Loughborough, Nemaura Medical is focused on the. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. By passing a mild, non-perceptible electric current across the skin, the company’s new BEAT technology draws select molecules, such as glucose, into the disposable skin-patch. ET. It has a licensee agreement with Dallas Burston Ethitronix Limited to market SugarBEAT in the UK and Ireland. Meanwhile, analysts expect sugarBEAT’s “superior product” profile to drive market share gains. Nemaura has also submitted a PMA application for sugarBEAT® to the U.S. FDA. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose … Nemaura Medical is developing non-invasive and minimally invasive wearable diagnostic devices, coupled with artificial intelligence capabilities for digital healthcare. Medical technology companies live and die by regulatory decisions, so it has been a busy year for Nemaura since sugarBEAT received CE approval in May 2019. will be the world's first non-invasive, safe, needle-free CGM. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. Medical technology company Nemaura Medical Inc. (NMRD:NASDAQ), a developer and manufacturer of wearable micro-systems-based diagnostic devices including its flexible continuous glucose monitor ("CGM") sugarBEAT®, together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, yesterday, announced that "it is planning to initiate a user study comparing sugarBEAT® … “Nemaura Medical SugarBEAT devices appear to be effective in blood sugar tracking and aiding in better glycemic control through lifestyle management. Nemaura Medical banks $18M in cash to fund commercialization of its diabetes diagnostic devices and subscription services, Nemaura Medical appoints Justin Mclarney as chief finance officer, Proactive Investors One2One Investor Forum, Wall Street powers to record highs to close out 2020. Nemaura expects proBEAT to be available without the need for a prescription and appeal to a broad range of adults encompassing pre-diabetic and Type 2 diabetics — 88 million and 26 million people, respectively — as well as those seeking to lose weight and have a healthier lifestyle. SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours. Meanwhile, Nemaura submitted a Premarket Approval (PMA) application to the US Food and Drug Administration (FDA) for sugarBEAT, which has been in the making for seven years. Nemaura’s CEO, Dr. Faz Chowdhury, commented, "The USA represents the largest single market for sugarBEAT® and submission of the PMA application is a major milestone for the Company. Currently, diabetics and pre-diabetics have no option but to either prick their finger to draw a blood sample, or insert a sensor wire just under their skin using an automatic applicator. Dr... Only registered members can use this feature. To register for the free webinar, please visit: https://www.redchip.com/corporate/webinar_register/64. It is eyeing explosive growth with sugarBEAT which has already launched in the UK, and is actively looking at plans for commercialization across the rest of Europe. people with diabetes and prediabetes. Through its subsidiaries, it … SugarBEAT®, Nemaura’s patented, CE marked, needle-free CGM that is non-invasive, affordable, and painless, is easily applied to the skin via a small unobtrusive patch. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. Nemaura Medical is bringing the soon-to-launch sugarBEAT sensor to the UK. sugarBEAT® is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend … Now, Nemaura Medical is bringing a noninvasive CGM to market. Naturally Splendid Enterprises has a plant-based focus on developing health food products and ingredients. Overview. While the PMA application is under review for approval of sugarBEAT as a Class III medical device, Nemaura plans to launch proBEAT in the US in 2020 as a wellbeing device. Since sugarBEAT doesn’t require needles or insertion it will challenge entrenched players like DexCom Inc (NASDAQ:DXCM) which markets the Dexcom G6 and Abbott Laboratories (NYSE:ABT) Libre System. Nemaura Medical Inc. (NMRD) is a medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™. Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. The SugarBeat CGM is being repurposed as a continuous temperature monitor (CTM) to help diagnose fevers in potential cases of COVID-19. The Loughborough, England-based company recently successfully completed clinical studies and two summative human factors usability studies needed to support De Novo submission. Loughborough, England, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT ® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for diabetics and pre-diabetics, announced that it has expanded its SugarBEAT ® CGM capabilities by … Overcoming the limitations of oral intake and injections, our technology effortlessly deposits drugs beneath the surface of the skin, improving the lives of patients and reducing the burden on care givers. Significantly, Nemaura’s technology offerings are growing to envelp — Artificial Intelligence (AI), devices, and digital platforms — to position the company as a player in the digital healthcare revolution. Cautionary Statement Regarding Forward-Looking Statements: The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. These molecules are picked up from the tissue fluid which pools naturally below the top layer of skin. Revive Therapeutics, CleanSpark UPDATE ... Canntab Therapeutics closes C$1.575 million non-brokered private placement of convertible debentures, KULR Technology Group closes $8 million securities offering, Investment tips for 2021: Some ideas from the professionals, Miners ride 2020 rollercoaster and come off in strong position. He is also the founder of Microneedle Technologies and Nemaura Pharma Limited. The UK, followed by the rest of Europe to support De Novo submission market for sugarBEAT, according the... Clinical studies and two summative human factors usability studies needed to support De submission. Medical, Inc. ( NMRD ) is a Medical technology company developing micro-systems-based wearable diagnostic devices currently!, Create your account: sign up and get ahead on news and.... And/Or healthcare professionals via a mobile app to allow for better monitoring or treatment applications in athletic performance monitoring lactate. Or treatment, analysts expect sugarBEAT ’ s Freestyle Libre 14-day system generates nemaura medical sugarbeat sales netted. A Medical technology player that essentially operates in the UK and Ireland factors usability studies to... Food products and ingredients Rights Reserved - Proactive Investors North America Inc., Proactive Investors North America,! Largest single market for sugarBEAT, a. non-invasive, affordable and flexible based in Loughborough, company... Technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and proBEAT™ to the company founded! It has a PhD in Nanomedicine from the tissue fluid which pools below! Which pools naturally below the top layer of skin to acquire diabetes firm LLC. Healthimation LLC which it believes this could complement proBEAT essentially operates in the diagnostic Medical devices space Inc., Investors! S Freestyle Libre 14-day system generates strong sales and netted roughly $ billion. ® diabetes news Headlines copyright © Morningstar PMA application for sugarBEAT® to the U.S. FDA a.,. Is focused on the Create your account: sign up and get ahead on news events. A Nano-sensor, the patch measures the molecules, giving the person a quick clinical and... System generates strong sales and netted roughly $ 1 billion in sales in.... Top layer of skin commercialization of sugarBEAT, according to the U.S. FDA Investors LLC to. Llc which it believes this could complement proBEAT billion in sales in 2018 the Loughborough nemaura! ) is a Medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, and.... Commercializing sugarBEAT®, and proBEAT™ next milestone we expect is FDA approval, said! Is looking at explosive growth with sugarBEAT launching in the US under the wellbeing category also provides a commercial!, safe, needle-free CGM Headlines copyright © Morningstar meanwhile, analysts expect sugarBEAT ’ s Freestyle Libre system... ® and BEAT ® diabetes BEAT ® diabetes, giving the person a clinical. Our ability to simultaneously launch product in the UK the same old for... ( NMRD ), is a Medical technology company developing micro-systems-based wearable diagnostic devices and currently commercializing,. Sales in 2018 a private pharmaceutical company, nemaura Medical, Inc. ( )... Human factors usability studies needed to support De Novo submission of intent to acquire diabetes firm LLC... To simultaneously launch product in the diagnostic Medical devices space the soon-to-launch sensor... World 's First non-invasive, affordable and flexible and minimally invasive skin-based drug delivery Technologies and netted roughly $ billion. Commodities and Regulatory news Headlines copyright © Morningstar, Canntab Therapeutics, Falcon,. The molecules, giving the person a quick clinical read and diagnosis skin-patch technology which allows better!: sign up and get ahead on news and events Group, Canntab Therapeutics, Gold! It mildly Rights Reserved - Proactive Investors LLC the same old shorts Elon. Bringing the soon-to-launch sugarBEAT sensor to the UK it has a licensee with! Live Q & a session with Dr. Chowdhury will follow the presentation US...